PaulKwoMD

Gastroenterology • Stanford, CA

Hepatology & Liver Transplantation

Professor of Medicine, Stanford University

Join to view full profile

Dr. Kwo is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kwo's full profile

Already have an account?

Office
300 Pasteur Dr
Stanford, CA 94305
Phone+1 650-723-4000

Education & Training

Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Gastroenterology, 1992 - 1995
University of MarylandResidency, Internal Medicine, 1988 - 1991
Wayne State University School of MedicineClass of 1988

Certifications & Licensure

CA State Medical License 2016 - 2025
IN State Medical License 1995 - 2017
MN State Medical License 1992 - 1995
MD State Medical License 1990 - 1992
American Board of Internal Medicine Gastroenterology
American Board of Internal Medicine Transplant Hepatology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2003-2014
Indianapolis Monthly Castle Connolly, 2007, 2009-2011, 2013
Fellow (FACG) American College of Gastroenterology

Clinical Trials

Study of Telaprevir in Subjects With Hepatic Impairment Start of enrollment: 2007 Sep 01
Completed
Phase 1
Pilot Study With Peginterferon, Ribavirin, and Boceprevir Prior to Transplantation to Clear Virus in Hepatitis C Genotype 1 Infected Individuals Undergoing Orthotopic Liver Transplantation Start of enrollment: 2013 Jun 01
Completed
Early Phase 1
Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study) Start of enrollment: 2014 Jul 28
Completed
Phase 2
Phase 3 Study to Evaluate the Efficacy and Safety of Peginterferon Lambda for 48 Weeks in Patients With Chronic HDV Start of enrollment: 2021 Dec 21
Active, not recruiting
Phase 3
Roles: Contact, Principal Investigator
Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a Start of enrollment: 2018 Dec 01
Completed
Phase 3
Roles: Principal Investigator, Contact
Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein Start of enrollment: 2023 Mar 06
Recruiting
Phase 3
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

223 citations
A Randomized, Double-Blinded, Placebo-Controlled Multicenter Trial of Etanercept in the Treatment of Alcoholic Hepatitis
Nicholas C. Boetticher, Craig J. Peine, Paul Y. Kwo, Gary A. Abrams, Tushar Patel
Gastroenterology. 2008-12-01
519 citations
Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infe...
Paul Y. Kwo, Eric Lawitz, Jonathan McCone, Eugene R. Schiff, John M. Vierling
Lancet. 2010-08-28
196 citations
Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1
Thomas D. Boyer, Arun J. Sanyal, Florence Wong, R. Todd Frederick, John R. Lake
Gastroenterology. 2016-06-01

Journal Articles

Diagnosis and Management of Primary Biliary Cholangitis
Zobair M Younossi, Kris V Kowdley, Ira M Jacobson, Mitchell L Shiffman, Paul Kwo, Nature
Response to Perrella Et Al
Paul Y Kwo, Mitchell L Shiffman, Nature

Lectures

Liver Transplantation: Selection and Controversies
AGC 2018 Annual Scientific Meeting, Philadelphia, PA - 10/7/2018
Viral Hepatitis: Where We Are in 2018
AGC 2018 Annual Scientific Meeting, Philadelphia, PA - 10/6/2018

Authored Content

Reflections on Key Presentations at ACG 2021November 2021

Press Mentions

DURECT Corporation Announces Preliminary Data from the Ongoing DUR-928 Alcoholic Hepatitis Phase 2a TrialMay 7th, 2019
DURECT Corporation to Present Preliminary Data from the Ongoing DUR-928 Alcoholic Hepatitis Phase 2a Trial and Report First Quarter 2019 Financial ResultsMay 3rd, 2019
Phase 2 Data Show Treatment Efficacy in 'Difficult-to-Cure' Hepatitis C PatientsApril 16th, 2016
Join now to see all

Grant Support

Alcohol Utilization Rates Determined By Alcohol Clamping--Effect Of Age, GenderNational Center For Research Resources1997–2002

Professional Memberships

American College of Gastroenterology - ACG
Fellow